Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
Stopped DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized subjects were followed up to W40.
Conditions
Interventions
- DRUG: EYP001a
- DRUG: Placebo
- DRUG: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Sponsor
Enyo Pharma
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]